A trial comparing temozolomide with dacarbazine for advanced melanoma skin cancer (EORTC 18032)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Melanoma
Skin cancer

Status:

Results

Phase:

Phase 3

This trial compared temozolomide with dacarbazine for people with advanced melanoma that could not be removed with an operation.

Doctors usually treat advanced melanoma with chemotherapy. The most commonly used drug is dacarbazine (DTIC). Another chemotherapy drug called temozolomide can also be helpful for this group of patients.

In this trial doctors compared dacarbazine with a higher dose of temozolomide, given more often than the standard dose.

The aims of this trial were to

  • See if temozolomide at a higher, more frequent dose worked better than dacarbazine for advanced melanoma
  • Find out more about the side effects

Summary of results

The trial team found that having higher dose temozolomide more frequently than the standard dose was no better than dacarbazine for people with advanced melanoma.

The trial recruited 859 people

  • Half had temozolomide
  • Half had dacarbazine

About 18 months after treatment had finished, the researchers looked at how long people lived for. They found there was no difference between the 2 treatment groups.

The main side effect for people in both groups was a drop in blood counts. This was slightly worse for the people who had temozolomide.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor P. Patel

Supported by

Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
NIHR Clinical Research Network: Cancer
Schering Plough

Other information

This is Cancer Research UK trial number CRUKE/04/017.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 547

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think